Pulmatrix (PULM) PE Ratio: History & Chart

Pulmatrix, Inc.(PULM)

Biotechnology · Framingham, MA

$1.43-0.05 (-3.38%)

Delayed quote: Oct 6, 2026, 3:39 PM EDT

About Pulmatrix, Inc.

Pulmatrix, Inc. (PULM) is a clinical-stage biotechnology firm focused on creating and advancing inhaled treatments. The company's primary goal is to address significant unmet medical needs in respiratory and other diseases within the United States. Central to their approach is the innovative iSPERSE (inhaled small particles easily respirable and emitted) technology. This proprietary platform allows for the precise delivery of both small and large molecule therapeutics directly into the lungs, achieving either localized effects or systemic distribution throughout the body. Pulmatrix's development pipeline includes several key candidates: Pulmazole: An inhaled antifungal drug being developed to treat allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis. PUR1800: A narrow spectrum kinase inhibitor currently undergoing Phase 1b clinical trials for individuals suffering from stable moderate-to-severe chronic obstructive pulmonary disease (COPD). PUR3100: An iSPERSE-formulated version of dihydroergotamine, intended for the rapid relief of acute migraine attacks. The company also maintains strategic collaborations, including a licensing arrangement with RespiVert Ltd. for access to a range of kinase inhibitor drug candidates, a partnership with Cipla Technologies LLC for the development and commercialization of Pulmazole, and a collaboration and license agreement with Sensory Cloud, Inc. Established in 2003, Pulmatrix, Inc. is headquartered in Lexington, Massachusetts.

Framingham, MA

2 employees

www.pulmatrix.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Peter Ludlum

View full financials

NAME	MARKET CAP	PE RATIO	TTM	3Y	5Y
Pulmatrix, Inc. (PULM)	$5.22M	N/A	N/A	N/A	N/A
Alzamend Neuro Inc (ALZN)vs ›	$5.23M	N/A	N/A	N/A	N/A
Lunai Bioworks Inc. (LNAI)vs ›	$5.21M	N/A	N/A	N/A	N/A
Gelteq Limited Ordinary Shares (GELS)vs ›	$5.32M	N/A	N/A	N/A	N/A
Basel Medical Group Ltd Ordinary Shares (BMGL)vs ›	$5.17M	N/A	N/A	N/A	N/A
Lexaria Bioscience Corp. (LEXX)vs ›	$5.27M	N/A	N/A	N/A	N/A
Intelligent Bio Solutions Inc. (INBS)vs ›	$5.24M	N/A	N/A	N/A	N/A
Soligenix, Inc. (SNGX)vs ›	$5.33M	N/A	56.51	56.51	56.51
Liminatus Pharma, Inc. Class A Common Stock (LIMN)vs ›	$5.06M	N/A	N/A	N/A	N/A
Xenetic Biosciences, Inc. (XBIO)vs ›	$5.02M	N/A	N/A	N/A	N/A

NAME

MARKET CAP

PE RATIO

TTM

Pulmatrix, Inc. (PULM)

$5.22M

N/A

Alzamend Neuro Inc (ALZN)vs ›

$5.23M

N/A

Lunai Bioworks Inc. (LNAI)vs ›

$5.21M

N/A

Gelteq Limited Ordinary Shares (GELS)vs ›

$5.32M

N/A

Basel Medical Group Ltd Ordinary Shares (BMGL)vs ›

$5.17M

N/A

Lexaria Bioscience Corp. (LEXX)vs ›

$5.27M

N/A

Intelligent Bio Solutions Inc. (INBS)vs ›

$5.24M

N/A

Soligenix, Inc. (SNGX)vs ›

$5.33M

N/A

56.51

Liminatus Pharma, Inc. Class A Common Stock (LIMN)vs ›

$5.06M

N/A

Xenetic Biosciences, Inc. (XBIO)vs ›

$5.02M

N/A

PE Ratio Formula & Definition

PE Ratio = Share Price / Diluted EPS (TTM)

The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.

PE Ratio: N/A

PULM PE Ratio Metrics

PULM Competitors' PE Ratio

P/E Comparison

Forward P/E Calculation

PE Ratio Formula & Definition

Related Metrics